|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
RGD |
Samsum Ant Venom Exerts Anticancer Activity Through Immunomodulation In Vitro and In Vivo.
|
29634416 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrated that HBV suppressed apoptosis of hepatoma cells by up-regulating miR-181a expression and down-regulating Fas expression, which may provide a new understanding of the mechanism in HBV-related HCC pathogenesis.
|
25449696 |
2015 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The CD95 rs1800682A/G site polymorphism may be associated with hepatocellular carcinoma susceptibility.
|
25723590 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that HDAC2 silencing in HCC cells also strongly inhibited PPARγ signaling and other regulators of glycolysis (ChREBPα and GLUT4) and lipogenesis (SREBP1C and FAS), eliciting a marked decrease in fat accumulation.
|
24958469 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Shikonin inhibited HepG2 cells, possibly through the pathway of inducing early apoptosis, and was beneficial for restoring the apoptotic sensitivity of HepG2 cells by CD95, and should therefore be considered as a candidate agent for the prevention or treatment of human hepatoma.
|
21164560 |
2010 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, -1377G>A in Fas promoter region showed protective effect to HCC occurrence (RH = 0.70, p = 0.03).
|
17938571 |
2007 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Fas stimulation activates NF-kappaB in SK-Hep1 hepatocellular carcinoma cells.
|
12883671 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, the intensity of Fas protein expression was significantly greater in the liver specimens of the patients who developed HCC than in those who did not (p = 0.015).
|
11873109 |
2002 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Overexpression of the mouse Fas gene in human Hep3B hepatoma cells overcomes their resistance to Fas-mediated apoptosis.
|
11867183 |
2002 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Functional p53 appears to be a major factor for CD95 expression in hepatocytes, the loss of which could contribute to chemoresistance and possibly immune evasion in hepatocellular carcinoma.
|
11692157 |
2001 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that the expression of sFas and FAP-1 and, in part, loss of Fas expression, rather than Fas gene alteration or bcl-2 expression, may be involved in the Fas resistance of HCC in vivo and that these mechanisms may play important roles in the pathogenesis of human HCC.HUM PATHOL 32:250-256.
|
11274632 |
2001 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reporter gene experiments in hepatoma cell lines with a Fas promoter-luciferase construct indicated that the repression of Fas (CD95) mRNA by IkappaBalpha was transcriptionally mediated.
|
10692445 |
2000 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study investigated whether different variants of hepatitis C virus core or E2 protein interfere with tumour necrosis factor alpha or Fas (CD95/ APO-1) antibody-induced programmed cell death in transiently transfected human hepatoma (HepG2) cells.
|
10583438 |
1999 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bleomycin did not increase CD95 in hepatoma cells with mutated p53 (Huh7) or in hepatoma cells which were p53-/- (Hep3B).
|
9022073 |
1997 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
All HCCs had partially or completely lost the expression of the CD95 receptor constitutively expressed by normal liver cells and might thus evade CD95-mediated killing.
|
8946836 |
1996 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
HPO |
|
|
|